Best new maintenance treatments for ovarian cancer

November 5, 2026Written by Navis AI

TL;DR: After initial ovarian cancer treatment, newer maintenance drugs called PARP inhibitors can help prevent cancer from coming back, especially if you have specific genetic changes—but which treatment is best depends on your individual situation.

KEY POINTS:

  • PARP inhibitors (olaparib, niraparib, veliparib) are now standard maintenance options after first-line chemotherapy and have shown significant benefits in delaying cancer recurrence
  • If you have a BRCA1/2 mutation, PARP inhibitors offer the strongest benefit and are preferred over other options
  • Even without a BRCA mutation, PARP inhibitors may help if your tumor shows homologous recombination deficiency (HRD)—a specific pattern of DNA damage
  • Bevacizumab (an anti-angiogenesis drug that cuts off blood supply to tumors) remains an option for patients without BRCA mutations
  • Your specific genetic testing results, stage of disease, and how well you responded to initial treatment all determine which maintenance therapy is right for you

NEXT STEP: Ask your oncologist whether you've had complete genetic and molecular testing (BRCA1/2, HRD status) to determine which maintenance options apply to your specific situation.


Tell us what’s going on with your cancer. 2 free answers, then a free account.

FULL ANSWER

Understanding Maintenance Therapy for Ovarian Cancer

After you complete initial treatment for ovarian cancer (usually surgery followed by chemotherapy), your care team may recommend maintenance therapy—additional treatment designed to prevent or delay cancer recurrence. According to the NCCN Guidelines for Ovarian Cancer (2025), maintenance therapy has become an important part of treatment planning for patients with advanced-stage disease.

Think of maintenance therapy like this: initial chemotherapy is the "attack" phase that shrinks visible tumors. Maintenance therapy is the "defense" phase that helps keep any remaining microscopic cancer cells from growing back.


The New Standard: PARP Inhibitors

PARP inhibitors are a class of targeted drugs that have revolutionized ovarian cancer maintenance treatment. PARP stands for "poly-ADP-ribose polymerase"—an enzyme that helps cancer cells repair their DNA. By blocking this enzyme, PARP inhibitors make it harder for cancer cells to survive.

According to NCCN Guidelines, several PARP inhibitors have been FDA-approved for ovarian cancer maintenance:

  • Olaparib (Lynparza)
  • Niraparib (Zejula)
  • Veliparib (Abrysvo)

How Well Do They Work?

The clinical trial data is compelling. Here's what the research shows:

For patients with BRCA1/2 mutations:

  • In the SOLO-1 trial, patients taking olaparib maintenance had a 60% chance of being cancer-free at 3 years, compared to only 27% for those on placebo
  • This represents a dramatic improvement in progression-free survival (the time before cancer returns)

For patients without BRCA mutations but with HRD (homologous recombination deficiency):

  • PRIMA trial: niraparib showed a median progression-free survival of 21.9 months versus 10.4 months with placebo
  • PAOLA-1 trial: olaparib combined with bevacizumab showed 28.1 months versus 16.6 months with bevacizumab alone

For patients with wild-type BRCA (no mutation) and no HRD:

  • Benefits are more modest, and according to NCCN Guidelines, the Panel considers PARP inhibitor use in these patients to be of "minimal benefit"

The Role of Genetic Testing

This is critical: which maintenance therapy works best depends on your tumor's genetic profile.

According to NCCN Guidelines, validated molecular testing should be performed in a CLIA-approved laboratory and should include:

  • BRCA1/2 mutation status (germline and somatic)
  • HRD (homologous recombination deficiency) status
  • Other markers like MSI (microsatellite instability), MMR (mismatch repair), and TMB (tumor mutational burden)

Why does this matter?

  • If you have a BRCA1/2 mutation, PARP inhibitors are your strongest option
  • If you don't have a BRCA mutation but have HRD, you still benefit from PARP inhibitors, though the benefit is somewhat less
  • If you have neither BRCA mutation nor HRD, other maintenance options may be more appropriate

Other Maintenance Options

Bevacizumab (Avastin)

Bevacizumab is an anti-angiogenesis drug—it works by cutting off the blood supply that tumors need to grow. According to NCCN Guidelines, bevacizumab remains a recommended maintenance option for:

  • Patients with wild-type or unknown BRCA status who completed first-line chemotherapy with a bevacizumab-containing regimen
  • Patients who are not candidates for PARP inhibitors

The GOG-0218 and ICON7 trials showed that bevacizumab maintenance improved progression-free survival in advanced ovarian cancer patients.

Observation (Watchful Waiting)

For patients with early-stage disease (Stage I) who had no signs of cancer spread, NCCN Guidelines recommend observation with regular follow-up rather than maintenance therapy. Your care team will monitor you closely with clinical exams and imaging.


How Treatment Decisions Are Made

According to NCCN Guidelines, your oncologist will consider:

  1. Your disease stage (how far the cancer had spread at diagnosis)
  2. Your response to initial treatment (complete response, partial response, or stable disease)
  3. Your genetic test results (BRCA status, HRD status)
  4. Your overall health and ability to tolerate side effects
  5. Your preferences and goals for treatment

The guidelines emphasize that "patients, doctors, and other health care professionals" should work together in shared decision-making. This means your voice matters—your concerns about side effects, quality of life, and treatment goals should all be part of the conversation.


Important Questions to Ask Your Oncologist

  1. Have I had complete molecular testing? Specifically, do you know my BRCA1/2 status and HRD status?

  2. What was my response to initial chemotherapy? (Complete response, partial response, or stable disease?)

  3. Based on my specific results, which maintenance options does my care team recommend?

  4. What are the potential side effects of the recommended maintenance therapy, and how are they managed?

  5. How long would I take maintenance therapy, and how will we know if it's working?

  6. Are there clinical trials available that might be appropriate for my situation?

  7. What happens if I choose not to have maintenance therapy?


The Bottom Line

Maintenance therapy for ovarian cancer has evolved significantly. PARP inhibitors represent a major advance, particularly for patients with BRCA mutations or HRD-positive tumors. According to NCCN Guidelines, these drugs have become standard recommendations for many patients after first-line chemotherapy.

However, there is no one-size-fits-all approach. Your specific genetic profile, disease characteristics, and personal circumstances will determine which maintenance therapy—if any—is right for you.

The most important step is ensuring you've had comprehensive genetic and molecular testing, then having a detailed conversation with your oncology team about what the results mean for your treatment plan.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your next question, already answered

Tap to keep going. 2 free answers, then a free account.

Ask Navis about your case

That answer is general. Ask about your specific situation. Answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

  • Built by OpenCancer’s team of physician-scientists and cancer survivors.
  • Last updated November 5, 2026. Informational only — not a substitute for your oncology team.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

More questions about General